Green tea polyphenols, epicatechin gallate and epigallocatechin gallate, alleviated aberrant metabolic changes caused by olanzapine in rats. [PDF]
Hoseini E +4 more
europepmc +1 more source
Longitudinal effects of atypical antipsychotic drugs on body composition in first-episode and chronic schizophrenia patients. [PDF]
Xiang Q, Ma Y, Li M, Chai X, Li Y.
europepmc +1 more source
Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. [PDF]
Launders N +6 more
europepmc +1 more source
Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study. [PDF]
Gao W, Xu Y, Shan F, Liang J, Xia Q.
europepmc +1 more source
Exploring High-Dose Olanzapine for Psychosis in an Adolescent With Treatment-Resistant Schizophrenia. [PDF]
Aggarwal S, Sahu SP, Shah P, Knobles MJ.
europepmc +1 more source
Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring. [PDF]
Aljead M, Qashta A, Jalal Z, Jones AM.
europepmc +1 more source
Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia. [PDF]
Cao Y +5 more
europepmc +1 more source
Managing treatment-resistant schizophrenia following clozapine cessation: a case report of xanomeline-trospium and olanzapine combination therapy. [PDF]
Went NS +4 more
europepmc +1 more source
Psychotic major depressive disorder and rapid eye movement sleep behavior disorder cooccurring with a pineal cyst: a case report with neuroimaging insights in a 15-year-old female. [PDF]
Shu Y, Zhang Q, Hou Y, Liu J.
europepmc +1 more source

